PDL1 enriched tumors receiving anti-PD1/PDL1 monotherapy exhibit a 40–50% response to therapy and with the addition of chemotherapy this response rate can increase to 60–70% in NSCLC patients receiving 1st line therapy3. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.